Market Closed -
Other stock markets
|
Pre-market 07:52:52 am | |||
27 USD | +1.73% |
|
26.48 | -1.94% |
01:27pm | Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex | MT |
Jul. 15 | RBC Capital Upgrades Genmab to Outperform | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 25.37 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.55 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.20% | 16.92B | - | ||
+20.17% | 126B | B+ | ||
+24.67% | 118B | B+ | ||
+22.91% | 27.87B | B | ||
-17.74% | 20.95B | B+ | ||
-15.21% | 16.18B | B | ||
+11.91% | 14.84B | C+ | ||
-47.10% | 14.79B | A- | ||
+54.50% | 14.08B | C+ | ||
+151.63% | 12.57B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GMAB Stock
- GMAB Stock
- Ratings Genmab A/S